Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. - Wikidata - wikimedia - TriplyDB

Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

http://www.wikidata.org/entity/Q35363829

about

Worldwide trends in mortality from biliary tract malignancies.Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001 The significance of genetics for cholangiocarcinoma development Cancer and liver cirrhosis: implications on prognosis and management The role of the hepatitis viruses in cholangiocarcinoma Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.Genetic and molecular abnormalities in cholangiocarcinogenesis.Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy.Expression and diagnostic values of calretinin and CK5/6 in cholangiocarcinoma.MiR-590-3p suppresses epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma by inhibiting SIP1 expression.Gene expression profiling defined pathways correlated with fibroblast cell proliferation induced by Opisthorchis viverrini excretory/secretory product.Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease.Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.Chemopreventive and chemotherapeutic effect of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model.Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets.Cholangiocarcinoma: modern advances in understanding a deadly old disease Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial.Update on the management of cholangiocarcinoma.Apoptosis of human cholangiocarcinoma cells induced by ESC-3 from Crocodylus siamensis bile Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care.Clonorchis sinensis infestation promotes three-dimensional aggregation and invasion of cholangiocarcinoma cells Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors.Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.Cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease.Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes.Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma.Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma Risk factors for cholangiocarcinoma DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma.Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence Predictors and patterns of recurrence after curative liver resection in intrahepatic cholangiocarcinoma, for application of postoperative radiotherapy: a retrospective study A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma Diabetes mellitus and the risk of cholangiocarcinoma: an updated meta-analysis.Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine.

P2860

Q21093310-67C590B2-98D4-4329-900C-8F041E1F0A98 Q24651526-97BFFAC3-C3CA-4225-91E0-FCB8B085678D Q26865749-CF79093D-4AE2-483D-9A13-666BA73D3E25 Q28068579-EC266ED4-1397-4C39-B41F-4B96FF1B171D Q28288613-822CF9D3-A9B4-4C60-829A-9E1A34623A7C Q28293076-546F3EEB-A5D6-4BC9-A30F-9676150ADF6B Q33214444-2EF3C7FE-DDEC-445E-9E2F-925BA33B3544 Q33570262-442F3F54-F61B-4698-84C9-D31A9FF7A19A Q33608594-EB0574AA-13FE-4B52-BD38-26518069504B Q33654429-4037CB24-4E1C-4053-A24A-49FE622A9E69 Q33798552-4E936BE6-1E81-485B-8B4B-198E95EFAD38 Q33866823-45097E6C-FC4E-41CB-9F27-9C21E71DDCEE Q33866965-3BEBAE61-A570-4D69-8F35-03D50F0FC7F4 Q33961881-D623A2C1-0BD9-4CC1-94B7-B923AF6AA288 Q33977095-9BEA232F-0C69-4F01-A5E2-C35A8E8DE077 Q33998774-4E9DE907-FF43-4736-A4FB-F11D875662B4 Q34000079-6B4D0243-CE69-4F2E-AD4F-CED0C2F25C3E Q34045215-526DD82C-C205-40A0-8E79-58EC3DA941FB Q34153255-E4484D1E-A397-4045-831C-F9EC407E6B2E Q34169667-5CCB7C03-46C8-4041-9C72-76D9CCFCB49C Q34277315-C6B58B2F-C868-4283-85C8-1EBE3DA45595 Q34395425-C49F088E-934B-41B9-BC0C-5813DDDDA8FD Q34398255-4177E8F7-09B1-4D1C-A97C-A251075AB789 Q34528218-14972770-4493-4FEA-A27B-F2FA7A669D09 Q34661807-A6B0EF54-69CC-4BE0-AEE7-D9AD21090423 Q34699884-F77DB95B-89B2-4DC7-A18E-2F6D8E7EE1D9 Q34881846-FDA9BC0F-2A01-4194-B263-EB2248847E90 Q34904867-B62A9D25-D56E-4E4F-9E0B-879417549BA0 Q35010217-9532B893-FBB1-4D5C-844A-0FBE652ABE83 Q35074664-3346F4C4-7D33-4997-92D3-7C1961569E58 Q35595522-341C61D1-EDDE-47DD-A047-3D841DC8340A Q35607681-682FD20A-03A4-41AB-9717-F1071121F185 Q35674607-96C38957-5FBD-4001-B4EF-DDC6D3046E4E Q35768888-E273CD66-3584-451D-A576-CB379563741E Q35896512-79734EC0-628D-471B-8BBA-86B568FDD1F6 Q35952148-1F3A6DB9-5FB5-4070-B50E-821E2DA03E38 Q36094601-0DB39A41-BFA0-4562-8F4F-977F88D2771C Q36243908-0D1B157B-4821-47DF-BE62-0E9969EACCF7 Q36491569-607A7FEE-9B88-41CB-8596-636F2F7E631E Q36502644-1BC13605-3D2E-46BE-8B80-0875B5317158

P2860

Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

http://www.wikidata.org/entity/Q35363829

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Increase in mortality rates fr ...... n England and Wales 1968-1998.

@ast

Increase in mortality rates fr ...... n England and Wales 1968-1998.

@en

type

label

Increase in mortality rates fr ...... n England and Wales 1968-1998.

@ast

Increase in mortality rates fr ...... n England and Wales 1968-1998.

@en

prefLabel

Increase in mortality rates fr ...... n England and Wales 1968-1998.

@ast

Increase in mortality rates fr ...... n England and Wales 1968-1998.

@en

P1433

Q35363829-91182A94-F8CD-4F12-B3E6-BC1ECEB2037E

P1476

Q35363829-09BE4782-3882-48A1-8CBF-F903E4D18394

P2093

Q35363829-00AC7DCA-65CF-47E4-B358-41831D928CAF

Q35363829-039E11CF-CFC8-408F-9296-97F31B25374B

Q35363829-0980D302-CB49-437B-9E8D-FB81C850F273

Q35363829-69C49A06-4616-4BA2-9430-096FA1DFB932

Q35363829-7C2C8A76-BD21-4D51-A6A9-088E22BBF619

Q35363829-B457EFAF-431E-446A-BBE6-648A4E3357D7

Q35363829-BE2787FA-1A13-49F3-8595-138904691958

P2860

Q35363829-0155920E-1F0B-4CBA-AF18-6EF552029451

Q35363829-18BF3DEC-03D3-4E9F-BDCC-6BAB6C54AA3B

Q35363829-23F632F2-10DB-480D-8971-B09D74CEF288

Q35363829-2925BD6B-983E-447E-ABE7-B4D68B3100F4

Q35363829-3393C2F7-EFEC-4093-B20B-BFCCB4426F66

Q35363829-751D8D7A-6F93-4EF3-9216-51EF01B80C5D

Q35363829-BEFC9F79-F3A7-4375-87DB-D8A76193FECC

Q35363829-CACFC2DC-CAE8-418D-925E-25B0D04F032C

P304

Q35363829-97F0C4A7-205F-46A1-BAB3-2A1084F946DB

P31

Q35363829-CF8D4E33-4C32-40D2-A2D2-576AEED0FB5D

P356

Q35363829-DB575FE0-B8F1-4953-934C-76EDA91AACDE

P407

Q35363829-5EB4477A-97AE-48E4-907F-C1D0042F869E

P433

Q35363829-A6469B0D-F140-4753-95CE-C71803827D54

P478

Q35363829-D1674A41-5A97-478A-9DBB-F9D66F62F4DB

P50

Q35363829-6E489330-84F4-42EB-80DD-8D5B085CC9F5

Q35363829-85109CF6-B7A1-49D3-B882-173A7F93D363

P577

Q35363829-A9EBE89A-310B-4A15-B6BD-0743554A68AE

P698

Q35363829-88E5ABDF-1A50-4C7B-9C49-26341A01BDCD

P921

Q35363829-E76CECD4-EC06-4AA8-8FB3-3213719516AC

P932

Q35363829-E6F2A42A-3BE6-4D8C-ADF3-16670FC49692

P356

P1433

P1476

Increase in mortality rates fr ...... in England and Wales 1968-1998

@en

P2093

A Beck

http://www.w3.org/2001/XMLSchema#string

H C Thomas

http://www.w3.org/2001/XMLSchema#string

M B Toledano

http://www.w3.org/2001/XMLSchema#string

S A Khan

http://www.w3.org/2001/XMLSchema#string

S Arora

http://www.w3.org/2001/XMLSchema#string

S D Taylor-Robinson

http://www.w3.org/2001/XMLSchema#string

S Hargreaves

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark.

Cancer of the liver and the use of oral contraceptives.

The risk of liver neoplasia in relation to combined oral contraceptive use.

The kinetics of cellular proliferation in regenerating liver.

Epidemiological characteristics and risk factors of hepatocellular carcinoma.

Cholangiocarcinoma: a review.

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.

P304

816-820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.48.6.816

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11358902

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

1728314

http://www.w3.org/2001/XMLSchema#string